Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

Returns on capital

Coeptis Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-69.1%

avg -312.9%

ROIC

-71.7%

avg -103.9%

ROA

-60.1%

avg 124.4%

Analysis

ROA is currently the strongest return metric at -60.1% versus its period average of 124.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David Mehalick

Co-Founder, Chairman of the Board, Chief Executive Officer & PresidentUSD 597K57330.19K9.40%

Daniel Alexander Yerace

Co-Founder, Vice President of Operations & DirectorUSD 452K4370.53K2.01%

Brian Cogley

Chief Financial OfficerUSD 310.39K3922.50K0.64%

Christine Elise Sheehy

Co-Founder, VP of Compliance & Corporate SecretaryUSD 75K5864.03K1.82%

Compensation is shown in the reported currency; data updated Jun 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
-25.0% (2yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at -25.0% (2yr), giving you a quick read on expected growth from here.

Competitors

Who does Coeptis Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about COEP's management, answered from reported figures.

Who manages COEP?

Coeptis Therapeutics, Inc. (COEP) lists 4 active executives. The top listed executive is Daniel Alexander Yerace, Co-Founder, Vice President of Operations & Director.

Are COEP insiders buying or selling?

Recent insider activity shows net buying of $42.88M.